Zepbound is a prescription obesity drug containing tirzepatide, manufactured by Eli Lilly and approved for chronic weight management after receiving FDA approval for use in eligible adults with obesity or overweight with certain related conditions
Then, on April 30, 2026, FDA proposed excluding tirzepatide, semaglutide, and liraglutide from the 503B bulks list because FDA did not identify a clinical need for large-scale outsourcing facilities to compound them from bulk substances
Although only a small number of cardiomyocytes experience cell death due to apoptosis, activating apoptotic pathways can worsen cardiac dysfunction
Allowing the injection to warm to room temperature for 1530 minutes before injection reduces the thermal shock to surrounding tissue and can minimize stinging
An active Eden Membership is required ($39 for the first month, auto-renews at $99/month thereafter)